CO5690559A2 - BAYER HEALTHCARE AG. DRUGS CONTAINING VARDENAFIL CHLORHYDRATE TRIHYDRATE - Google Patents
BAYER HEALTHCARE AG. DRUGS CONTAINING VARDENAFIL CHLORHYDRATE TRIHYDRATEInfo
- Publication number
- CO5690559A2 CO5690559A2 CO05013218A CO05013218A CO5690559A2 CO 5690559 A2 CO5690559 A2 CO 5690559A2 CO 05013218 A CO05013218 A CO 05013218A CO 05013218 A CO05013218 A CO 05013218A CO 5690559 A2 CO5690559 A2 CO 5690559A2
- Authority
- CO
- Colombia
- Prior art keywords
- trihydrate
- chlorhydrate
- drugs containing
- bayer healthcare
- vardenafil hydrochloride
- Prior art date
Links
Abstract
1.- Procedimiento para la fabricación de medicamentos que contienen clorhidrato de vardenafilo trihidrato en forma sólida, caracterizado porquea) en la preparación del medicamento se utiliza clorhidrato de vardenafilo con un contenido de agua discrecional,b) el clorhidrato de vardenafilo se transforma substancialmente en la forma trihidrato en un intermedio de procesamiento o en el producto final.2.- Procedimiento conforme a la reivindicación 1, caracterizado porque como medicamento se fabrican comprimidos recubiertos.3.- Procedimiento conforme a las reivindicaciones 1 y 2, caracterizado porque el intermedio de procesamiento o el producto final o el comprimido recubierto se pone en contacto con gas humedecido el tiempo necesario para que se forme substancialmente el trihidrato.4.- Procedimiento conforme a la reivindicación 3, caracterizado porque como gas se utiliza aire.1.- Procedure for the manufacture of medicines containing vardenafil hydrochloride trihydrate in solid form, characterized in that a) in the preparation of the drug, vardenafil hydrochloride with a discretionary water content is used, b) vardenafil hydrochloride is substantially transformed into the Trihydrate form in a processing intermediate or in the final product. 2.- Method according to claim 1, characterized in that as a medicament coated tablets are manufactured. 3.- Procedure according to claims 1 and 2, characterized in that the processing intermediate or the final product or the coated tablet is contacted with moistened gas for the time necessary for the trihydrate to form substantially. 4. Method according to claim 3, characterized in that air is used as gas.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CO05013218A CO5690559A2 (en) | 2005-02-14 | 2005-02-14 | BAYER HEALTHCARE AG. DRUGS CONTAINING VARDENAFIL CHLORHYDRATE TRIHYDRATE |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CO05013218A CO5690559A2 (en) | 2005-02-14 | 2005-02-14 | BAYER HEALTHCARE AG. DRUGS CONTAINING VARDENAFIL CHLORHYDRATE TRIHYDRATE |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5690559A2 true CO5690559A2 (en) | 2006-10-31 |
Family
ID=42138709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO05013218A CO5690559A2 (en) | 2005-02-14 | 2005-02-14 | BAYER HEALTHCARE AG. DRUGS CONTAINING VARDENAFIL CHLORHYDRATE TRIHYDRATE |
Country Status (1)
Country | Link |
---|---|
CO (1) | CO5690559A2 (en) |
-
2005
- 2005-02-14 CO CO05013218A patent/CO5690559A2/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200806289A (en) | Sustained-release formulation of zonisamide | |
RS52831B (en) | Buprenorrphine wafer for drug substitution therapy | |
PT1957110T (en) | Process for manufacturing chewable dosage forms for drug delivery and products thereof | |
GT200500384A (en) | PHARMACEUTICAL DOSAGE METHODS ADMINISTRABLE SOLIDS BY ROUTE WITH MODIFIED RELEASE | |
AR060019A1 (en) | PHARMACEUTICAL COMPOSITION, PRODUCT AND TREATMENT METHOD FOR A COGNITIVE DISORDER AND USES OF AN ACETILCOLINESTERASE INHIBITOR AND A 5- HT6 ANTAGONIST IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A COGNITIVE DISORDER | |
MX2010005631A (en) | Novel cyclic hydrocarbon compounds for the treatment of diseases. | |
WO2007031887A3 (en) | Extended release pharmaceutical composition of metformin and a process for producing it | |
ATE538777T1 (en) | MEDICINAL PRODUCTS CONTAINING VARDENAFIL HYDROCHLORIDE TRIHYDRATE AND THEIR PRODUCTION PROCESS | |
TNSN08279A1 (en) | Bayer healthcare ag | |
BRPI0610780A2 (en) | disintegrating tablet pharmaceutical formulation, and methods for treating a patient in need of olanzapine treatment, and for producing the tablet pharmaceutical formulation | |
BRPI0520797B8 (en) | bilayer compressed pharmaceutical dosage form | |
IL213671A (en) | Pharmaceutical compositions comprising aleglitazar, process for their manufacture and use thereof in the preparation of medicaments | |
ZA200506992B (en) | Fibrate tablet and method for the production thereof | |
PE20120956A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING BUPRENORPHINE AND NALMEFENE | |
EP4265298A3 (en) | Salt | |
SG148120A1 (en) | An oral pharmaceutical and an oral care product | |
CO5690559A2 (en) | BAYER HEALTHCARE AG. DRUGS CONTAINING VARDENAFIL CHLORHYDRATE TRIHYDRATE | |
EA201270269A1 (en) | PHARMACEUTICAL TABLET CONTAINING ROSUVASTATIN CALCIUM | |
CO6410284A2 (en) | ORAL PHARMACEUTICAL COMPOSITION FOR USE IN RESPIRATORY DISEASES | |
CN102727515A (en) | Medicinal preparation for treating dermatophytosis | |
TH75887A (en) | ||
MX2010006317A (en) | Oral pharmaceutical composition with an antihistamine and decongestant. | |
EE200600045A (en) | A medicament for the treatment and prophylaxis of cancer, a pharmaceutical composition, a process for the preparation of a pharmaceutical composition | |
IN2013MU03389A (en) | ||
ECSP11011279A (en) | ORAL PHARMACEUTICAL COMPOSITION FOR USE IN RESPIRATORY DISEASES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |